| Trial ID: | L2575 |
| Source ID: | NCT03113110
|
| Associated Drug: |
Empagliflozin 10 Mg
|
| Title: |
Empagliflozin in Post-Transplantation Diabetes Mellitus
|
| Acronym: |
EMPTRA-DM
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Posttransplant Diabetes Mellitus
|
| Interventions: |
DRUG: Empagliflozin 10 mg
|
| Outcome Measures: |
Primary: OGTT-derived 2-hour blood glucose level, Mean change from baseline blood glucose levels of the 2h value after OGTT (75g glucose) after 1 month of empagliflozin monotherapy. Maximum tolerable change from baseline blood glucose levels should not exceed 30 mg/dL on average (100 mg/dL in each individual)., 4 weeks after start of Empagliflozin treatment |
|
| Sponsor/Collaborators: |
Sponsor: Medical University of Vienna
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
16
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2017-01-15
|
| Completion Date: |
2018-05-31
|
| Results First Posted: |
|
| Last Update Posted: |
2019-05-07
|
| Locations: |
Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Austria, Vienna, 1090, Austria
|
| URL: |
https://clinicaltrials.gov/show/NCT03113110
|
